context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
The U.S. GAAP purchase price allocated to the transaction was $ 695 million, which consisted of $ 350 million of cash consideration paid and estimated contingent consideration at the date of acquisition valued at approximately $ 345 million. The fair value of the contingent consideration was valued using a Monte Carlo simulation model using Level 3 inputs. The fair value is sensitive to changes in the forecasts of operating metrics, probability of success, and discount rates. Refer to Note 9, | text | 345 | monetaryItemType | text: <entity> 345 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. GAAP purchase price allocated to the transaction was $ 695 million, which consisted of $ 350 million of cash consideration paid and estimated contingent consideration at the date of acquisition valued at approximately $ 345 million. The fair value of the contingent consideration was valued using a Monte Carlo simulation model using Level 3 inputs. The fair value is sensitive to changes in the forecasts of operating metrics, probability of success, and discount rates. Refer to Note 9, </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
On February 25, 2025, in order to preserve the ongoing continuity of the development programs for selatogrel and cenerimod considering certain capital structuring steps announced by Idorsia to secure its ongoing operations, Viatris and Idorsia entered into a letter agreement to amend certain terms of the original agreements described above. Under the terms of the letter agreement, Viatris will receive additional territory rights in Japan, South Korea and certain other countries in the Asia-Pacific region for cenerimod, a $ 250 million reduction in contingent milestone payments, including $ 200 million of development milestones, and additional personnel to expedite transitioning the development programs to Viatris in exchange for Viatris assuming $ 100 million of Idorsia’s obligation to contribute to development costs. In addition, the letter agreement provides for the replacement of the joint development committee with a transition committee to oversee the transition of both development programs to Viatris. | text | 100 | monetaryItemType | text: <entity> 100 </entity> <entity type> monetaryItemType </entity type> <context> On February 25, 2025, in order to preserve the ongoing continuity of the development programs for selatogrel and cenerimod considering certain capital structuring steps announced by Idorsia to secure its ongoing operations, Viatris and Idorsia entered into a letter agreement to amend certain terms of the original agreements described above. Under the terms of the letter agreement, Viatris will receive additional territory rights in Japan, South Korea and certain other countries in the Asia-Pacific region for cenerimod, a $ 250 million reduction in contingent milestone payments, including $ 200 million of development milestones, and additional personnel to expedite transitioning the development programs to Viatris in exchange for Viatris assuming $ 100 million of Idorsia’s obligation to contribute to development costs. In addition, the letter agreement provides for the replacement of the joint development committee with a transition committee to oversee the transition of both development programs to Viatris. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther |
The goodwill of $ 19.5 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products, including additional indications, to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes. The acquisition did not have a material impact on the Company’s results of operations since the acquisition date or on a pro forma basis during the year ended December 31, 2024. | text | 19.5 | monetaryItemType | text: <entity> 19.5 </entity> <entity type> monetaryItemType </entity type> <context> The goodwill of $ 19.5 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products, including additional indications, to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes. The acquisition did not have a material impact on the Company’s results of operations since the acquisition date or on a pro forma basis during the year ended December 31, 2024. </context> | us-gaap:Goodwill |
During the first quarter of 2023, the Company completed the acquisition of Oyster Point for approximately $ 427.4 million in cash, which included $ 11 per share paid to Oyster Point stockholders through a tender offer, payment for vested share-based awards, and the repayment of the Oyster Point debt. | text | 427.4 | monetaryItemType | text: <entity> 427.4 </entity> <entity type> monetaryItemType </entity type> <context> During the first quarter of 2023, the Company completed the acquisition of Oyster Point for approximately $ 427.4 million in cash, which included $ 11 per share paid to Oyster Point stockholders through a tender offer, payment for vested share-based awards, and the repayment of the Oyster Point debt. </context> | us-gaap:BusinessCombinationConsiderationTransferred1 |
During the first quarter of 2023, the Company completed the acquisition of Oyster Point for approximately $ 427.4 million in cash, which included $ 11 per share paid to Oyster Point stockholders through a tender offer, payment for vested share-based awards, and the repayment of the Oyster Point debt. | text | 11 | perShareItemType | text: <entity> 11 </entity> <entity type> perShareItemType </entity type> <context> During the first quarter of 2023, the Company completed the acquisition of Oyster Point for approximately $ 427.4 million in cash, which included $ 11 per share paid to Oyster Point stockholders through a tender offer, payment for vested share-based awards, and the repayment of the Oyster Point debt. </context> | us-gaap:BusinessAcquisitionSharePrice |
In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. During the year ended December 31, 2023, the Company incurred acquisition related costs of approximately $ 22.8 million, which were recorded primarily in SG&A in the consolidated statement of operations. | text | 22.8 | monetaryItemType | text: <entity> 22.8 </entity> <entity type> monetaryItemType </entity type> <context> In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. During the year ended December 31, 2023, the Company incurred acquisition related costs of approximately $ 22.8 million, which were recorded primarily in SG&A in the consolidated statement of operations. </context> | us-gaap:BusinessCombinationAcquisitionRelatedCosts |
During the year ended December 31, 2023, adjustments were made to the preliminary purchase price recorded at January 3, 2023, and are reflected as “Measurement Period Adjustments” in the table below. The U.S. GAAP purchase price was $ 392.7 million, net of cash acquired. The allocation of the purchase price to the assets acquired and liabilities assumed for Oyster Point is as follows: | text | 392.7 | monetaryItemType | text: <entity> 392.7 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, adjustments were made to the preliminary purchase price recorded at January 3, 2023, and are reflected as “Measurement Period Adjustments” in the table below. The U.S. GAAP purchase price was $ 392.7 million, net of cash acquired. The allocation of the purchase price to the assets acquired and liabilities assumed for Oyster Point is as follows: </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet |
The Company recorded a step-up in the fair value of inventory of approximately $ 29.3 million, which was fully amortized during the year ended December 31, 2023 and was included in | text | 29.3 | monetaryItemType | text: <entity> 29.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company recorded a step-up in the fair value of inventory of approximately $ 29.3 million, which was fully amortized during the year ended December 31, 2023 and was included in </context> | us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory |
The identified intangible assets of $ 334.0 million are comprised of product rights and licenses related to a commercial asset, Tyrvaya®, for the treatment of dry eye disease, that have an estimated useful life of 10 years. Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. | text | 334.0 | monetaryItemType | text: <entity> 334.0 </entity> <entity type> monetaryItemType </entity type> <context> The identified intangible assets of $ 334.0 million are comprised of product rights and licenses related to a commercial asset, Tyrvaya®, for the treatment of dry eye disease, that have an estimated useful life of 10 years. Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles |
The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes. The operating results of Oyster Point have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of Oyster Point for the period from the acquisition date to December 31, 2023 were $ 41.7 million and net loss, net of tax, was approximately $ 163.1 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs. | text | 6.7 | monetaryItemType | text: <entity> 6.7 </entity> <entity type> monetaryItemType </entity type> <context> The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes. The operating results of Oyster Point have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of Oyster Point for the period from the acquisition date to December 31, 2023 were $ 41.7 million and net loss, net of tax, was approximately $ 163.1 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs. </context> | us-gaap:Goodwill |
The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes. The operating results of Oyster Point have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of Oyster Point for the period from the acquisition date to December 31, 2023 were $ 41.7 million and net loss, net of tax, was approximately $ 163.1 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs. | text | 41.7 | monetaryItemType | text: <entity> 41.7 </entity> <entity type> monetaryItemType </entity type> <context> The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes. The operating results of Oyster Point have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of Oyster Point for the period from the acquisition date to December 31, 2023 were $ 41.7 million and net loss, net of tax, was approximately $ 163.1 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs. </context> | us-gaap:Revenues |
The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes. The operating results of Oyster Point have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of Oyster Point for the period from the acquisition date to December 31, 2023 were $ 41.7 million and net loss, net of tax, was approximately $ 163.1 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs. | text | 163.1 | monetaryItemType | text: <entity> 163.1 </entity> <entity type> monetaryItemType </entity type> <context> The goodwill of $ 6.7 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes. The operating results of Oyster Point have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of Oyster Point for the period from the acquisition date to December 31, 2023 were $ 41.7 million and net loss, net of tax, was approximately $ 163.1 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs. </context> | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under development, for consideration of $ 281 million. The Company had previously entered into a Master Development Agreement with Famy Life Sciences on December 20, 2019 under which the Company obtained rights with respect to acquiring certain pharmaceutical products and a 13.5 % equity interest in Famy Life Sciences for $ 25.0 million. The investment was accounted for in accordance with ASC 321, | text | 281 | monetaryItemType | text: <entity> 281 </entity> <entity type> monetaryItemType </entity type> <context> On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under development, for consideration of $ 281 million. The Company had previously entered into a Master Development Agreement with Famy Life Sciences on December 20, 2019 under which the Company obtained rights with respect to acquiring certain pharmaceutical products and a 13.5 % equity interest in Famy Life Sciences for $ 25.0 million. The investment was accounted for in accordance with ASC 321, </context> | us-gaap:BusinessCombinationConsiderationTransferred1 |
On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under development, for consideration of $ 281 million. The Company had previously entered into a Master Development Agreement with Famy Life Sciences on December 20, 2019 under which the Company obtained rights with respect to acquiring certain pharmaceutical products and a 13.5 % equity interest in Famy Life Sciences for $ 25.0 million. The investment was accounted for in accordance with ASC 321, | text | 13.5 | percentItemType | text: <entity> 13.5 </entity> <entity type> percentItemType </entity type> <context> On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under development, for consideration of $ 281 million. The Company had previously entered into a Master Development Agreement with Famy Life Sciences on December 20, 2019 under which the Company obtained rights with respect to acquiring certain pharmaceutical products and a 13.5 % equity interest in Famy Life Sciences for $ 25.0 million. The investment was accounted for in accordance with ASC 321, </context> | us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners |
On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under development, for consideration of $ 281 million. The Company had previously entered into a Master Development Agreement with Famy Life Sciences on December 20, 2019 under which the Company obtained rights with respect to acquiring certain pharmaceutical products and a 13.5 % equity interest in Famy Life Sciences for $ 25.0 million. The investment was accounted for in accordance with ASC 321, | text | 25.0 | monetaryItemType | text: <entity> 25.0 </entity> <entity type> monetaryItemType </entity type> <context> On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a privately-owned research company with a complementary portfolio of ophthalmology therapies under development, for consideration of $ 281 million. The Company had previously entered into a Master Development Agreement with Famy Life Sciences on December 20, 2019 under which the Company obtained rights with respect to acquiring certain pharmaceutical products and a 13.5 % equity interest in Famy Life Sciences for $ 25.0 million. The investment was accounted for in accordance with ASC 321, </context> | us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent |
The transaction to acquire the remaining equity shares of Famy Life Sciences closed during the first quarter of 2023. The Company recognized a gain of $ 18.9 million during the first quarter of 2023 as a result of remeasuring its pre-existing 13.5 % equity interest in Famy Life Sciences to fair value, which was recognized as a component of | text | 18.9 | monetaryItemType | text: <entity> 18.9 </entity> <entity type> monetaryItemType </entity type> <context> The transaction to acquire the remaining equity shares of Famy Life Sciences closed during the first quarter of 2023. The Company recognized a gain of $ 18.9 million during the first quarter of 2023 as a result of remeasuring its pre-existing 13.5 % equity interest in Famy Life Sciences to fair value, which was recognized as a component of </context> | us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee |
The transaction to acquire the remaining equity shares of Famy Life Sciences closed during the first quarter of 2023. The Company recognized a gain of $ 18.9 million during the first quarter of 2023 as a result of remeasuring its pre-existing 13.5 % equity interest in Famy Life Sciences to fair value, which was recognized as a component of | text | 13.5 | percentItemType | text: <entity> 13.5 </entity> <entity type> percentItemType </entity type> <context> The transaction to acquire the remaining equity shares of Famy Life Sciences closed during the first quarter of 2023. The Company recognized a gain of $ 18.9 million during the first quarter of 2023 as a result of remeasuring its pre-existing 13.5 % equity interest in Famy Life Sciences to fair value, which was recognized as a component of </context> | us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners |
In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP purchase price allocated to the transaction was $ 325.0 million, which consisted of $ 281 million of cash consideration paid for the remaining equity shares and $ 43.9 million for the fair value of the pre-existing 13.5 % equity interest. | text | 325.0 | monetaryItemType | text: <entity> 325.0 </entity> <entity type> monetaryItemType </entity type> <context> In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP purchase price allocated to the transaction was $ 325.0 million, which consisted of $ 281 million of cash consideration paid for the remaining equity shares and $ 43.9 million for the fair value of the pre-existing 13.5 % equity interest. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet |
In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP purchase price allocated to the transaction was $ 325.0 million, which consisted of $ 281 million of cash consideration paid for the remaining equity shares and $ 43.9 million for the fair value of the pre-existing 13.5 % equity interest. | text | 281 | monetaryItemType | text: <entity> 281 </entity> <entity type> monetaryItemType </entity type> <context> In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP purchase price allocated to the transaction was $ 325.0 million, which consisted of $ 281 million of cash consideration paid for the remaining equity shares and $ 43.9 million for the fair value of the pre-existing 13.5 % equity interest. </context> | us-gaap:BusinessCombinationConsiderationTransferred1 |
In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP purchase price allocated to the transaction was $ 325.0 million, which consisted of $ 281 million of cash consideration paid for the remaining equity shares and $ 43.9 million for the fair value of the pre-existing 13.5 % equity interest. | text | 43.9 | monetaryItemType | text: <entity> 43.9 </entity> <entity type> monetaryItemType </entity type> <context> In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP purchase price allocated to the transaction was $ 325.0 million, which consisted of $ 281 million of cash consideration paid for the remaining equity shares and $ 43.9 million for the fair value of the pre-existing 13.5 % equity interest. </context> | us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 |
In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP purchase price allocated to the transaction was $ 325.0 million, which consisted of $ 281 million of cash consideration paid for the remaining equity shares and $ 43.9 million for the fair value of the pre-existing 13.5 % equity interest. | text | 13.5 | percentItemType | text: <entity> 13.5 </entity> <entity type> percentItemType </entity type> <context> In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction were recorded at their respective estimated fair values at the acquisition date. The U.S. GAAP purchase price allocated to the transaction was $ 325.0 million, which consisted of $ 281 million of cash consideration paid for the remaining equity shares and $ 43.9 million for the fair value of the pre-existing 13.5 % equity interest. </context> | us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners |
The amount allocated to IPR&D represents an estimate of the fair value of purchased in-process technology for research projects that, as of the closing date of the acquisition, had not reached technological feasibility and had no alternative future use. The fair value of IPR&D of $ 290.0 million was based on the excess earnings method, which utilizes forecasts of expected cash inflows (including estimates for ongoing costs) and other contributory charges. A discount rate of 23.9 % was utilized to discount net cash inflows to present values. IPR&D is accounted for as an indefinite-lived intangible asset and will | text | 290.0 | monetaryItemType | text: <entity> 290.0 </entity> <entity type> monetaryItemType </entity type> <context> The amount allocated to IPR&D represents an estimate of the fair value of purchased in-process technology for research projects that, as of the closing date of the acquisition, had not reached technological feasibility and had no alternative future use. The fair value of IPR&D of $ 290.0 million was based on the excess earnings method, which utilizes forecasts of expected cash inflows (including estimates for ongoing costs) and other contributory charges. A discount rate of 23.9 % was utilized to discount net cash inflows to present values. IPR&D is accounted for as an indefinite-lived intangible asset and will </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles |
The goodwill of $ 89.2 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes. The acquisition did not have a material impact on the Company’s results of operations since the acquisition date or on a pro forma basis for the years ended December 31, 2023 and 2022. | text | 89.2 | monetaryItemType | text: <entity> 89.2 </entity> <entity type> monetaryItemType </entity type> <context> The goodwill of $ 89.2 million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes. The acquisition did not have a material impact on the Company’s results of operations since the acquisition date or on a pro forma basis for the years ended December 31, 2023 and 2022. </context> | us-gaap:Goodwill |
During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a component of | text | 69.9 | monetaryItemType | text: <entity> 69.9 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a component of </context> | us-gaap:OtherNonoperatingIncomeExpense |
During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a component of | text | 168.0 | monetaryItemType | text: <entity> 168.0 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a component of </context> | us-gaap:OtherNonoperatingIncomeExpense |
During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a component of | text | 17.7 | monetaryItemType | text: <entity> 17.7 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, the Company recognized TSA income related to all divestitures of approximately $ 69.9 million, $ 168.0 million, and $ 17.7 million, respectively. TSA income is recorded as a component of </context> | us-gaap:OtherNonoperatingIncomeExpense |
In the third quarter of 2023, Viatris executed an agreement to divest its women’s healthcare business to Insud Pharma, S.L., a leading Spanish multinational pharmaceutical company. The divestiture of the women’s healthcare business was primarily related to our oral and injectable contraceptives and did not include all of our women’s healthcare related products. The transaction included two manufacturing facilities in India. Assets and liabilities associated with the women’s healthcare business divested were classified as held for sale in the consolidated balance sheet as of December 31, 2023. The transaction closed in March 2024 and during the year ended December 31, 2024, the Company recognized a pre-tax gain on sale of approximately $ 77.8 million for the difference between the consideration received and the carrying value of the assets transferred (including an allocation of goodwill), which was recorded as a component of | text | 77.8 | monetaryItemType | text: <entity> 77.8 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, Viatris executed an agreement to divest its women’s healthcare business to Insud Pharma, S.L., a leading Spanish multinational pharmaceutical company. The divestiture of the women’s healthcare business was primarily related to our oral and injectable contraceptives and did not include all of our women’s healthcare related products. The transaction included two manufacturing facilities in India. Assets and liabilities associated with the women’s healthcare business divested were classified as held for sale in the consolidated balance sheet as of December 31, 2023. The transaction closed in March 2024 and during the year ended December 31, 2024, the Company recognized a pre-tax gain on sale of approximately $ 77.8 million for the difference between the consideration received and the carrying value of the assets transferred (including an allocation of goodwill), which was recorded as a component of </context> | us-gaap:GainLossOnSaleOfBusiness |
In the third quarter of 2023, Viatris also entered into a separate agreement to divest its rights to women’s healthcare products Duphaston® and Femoston® in certain countries to Theramex HQ UK Limited, a leading global specialty pharmaceutical company dedicated to women’s health. The transaction (other than in the U.K.) closed in December 2023, and upon closing, the Company recognized a pre-tax gain on sale of approximately $ 156.2 million in that quarter for the difference between the consideration received and the carrying value of the assets transferred. In the third quarter of 2024, the Company closed the divestiture of the product rights to Duphaston® and Femoston® in the U.K. to Insud Pharma, S.L., and recognized a pre-tax gain on sale of approximately $ 10.8 million. The respective pre-tax gains were recorded as a component of | text | 156.2 | monetaryItemType | text: <entity> 156.2 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, Viatris also entered into a separate agreement to divest its rights to women’s healthcare products Duphaston® and Femoston® in certain countries to Theramex HQ UK Limited, a leading global specialty pharmaceutical company dedicated to women’s health. The transaction (other than in the U.K.) closed in December 2023, and upon closing, the Company recognized a pre-tax gain on sale of approximately $ 156.2 million in that quarter for the difference between the consideration received and the carrying value of the assets transferred. In the third quarter of 2024, the Company closed the divestiture of the product rights to Duphaston® and Femoston® in the U.K. to Insud Pharma, S.L., and recognized a pre-tax gain on sale of approximately $ 10.8 million. The respective pre-tax gains were recorded as a component of </context> | us-gaap:GainLossOnSaleOfBusiness |
In the third quarter of 2023, Viatris also entered into a separate agreement to divest its rights to women’s healthcare products Duphaston® and Femoston® in certain countries to Theramex HQ UK Limited, a leading global specialty pharmaceutical company dedicated to women’s health. The transaction (other than in the U.K.) closed in December 2023, and upon closing, the Company recognized a pre-tax gain on sale of approximately $ 156.2 million in that quarter for the difference between the consideration received and the carrying value of the assets transferred. In the third quarter of 2024, the Company closed the divestiture of the product rights to Duphaston® and Femoston® in the U.K. to Insud Pharma, S.L., and recognized a pre-tax gain on sale of approximately $ 10.8 million. The respective pre-tax gains were recorded as a component of | text | 10.8 | monetaryItemType | text: <entity> 10.8 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, Viatris also entered into a separate agreement to divest its rights to women’s healthcare products Duphaston® and Femoston® in certain countries to Theramex HQ UK Limited, a leading global specialty pharmaceutical company dedicated to women’s health. The transaction (other than in the U.K.) closed in December 2023, and upon closing, the Company recognized a pre-tax gain on sale of approximately $ 156.2 million in that quarter for the difference between the consideration received and the carrying value of the assets transferred. In the third quarter of 2024, the Company closed the divestiture of the product rights to Duphaston® and Femoston® in the U.K. to Insud Pharma, S.L., and recognized a pre-tax gain on sale of approximately $ 10.8 million. The respective pre-tax gains were recorded as a component of </context> | us-gaap:GainLossOnSaleOfBusiness |
The OTC Business divested met the criteria to be classified as held for sale on October 1, 2023. As such, the related assets and liabilities were classified as held for sale in the consolidated balance sheet as of December 31, 2023. Upon classification as held for sale in the fourth quarter of 2023, we recognized a total charge of approximately $ 734.7 million, which was comprised of a goodwill impairment charge of approximately $ 580.1 million (recorded as a component of | text | 734.7 | monetaryItemType | text: <entity> 734.7 </entity> <entity type> monetaryItemType </entity type> <context> The OTC Business divested met the criteria to be classified as held for sale on October 1, 2023. As such, the related assets and liabilities were classified as held for sale in the consolidated balance sheet as of December 31, 2023. Upon classification as held for sale in the fourth quarter of 2023, we recognized a total charge of approximately $ 734.7 million, which was comprised of a goodwill impairment charge of approximately $ 580.1 million (recorded as a component of </context> | us-gaap:AssetImpairmentCharges |
The OTC Business divested met the criteria to be classified as held for sale on October 1, 2023. As such, the related assets and liabilities were classified as held for sale in the consolidated balance sheet as of December 31, 2023. Upon classification as held for sale in the fourth quarter of 2023, we recognized a total charge of approximately $ 734.7 million, which was comprised of a goodwill impairment charge of approximately $ 580.1 million (recorded as a component of | text | 580.1 | monetaryItemType | text: <entity> 580.1 </entity> <entity type> monetaryItemType </entity type> <context> The OTC Business divested met the criteria to be classified as held for sale on October 1, 2023. As such, the related assets and liabilities were classified as held for sale in the consolidated balance sheet as of December 31, 2023. Upon classification as held for sale in the fourth quarter of 2023, we recognized a total charge of approximately $ 734.7 million, which was comprised of a goodwill impairment charge of approximately $ 580.1 million (recorded as a component of </context> | us-gaap:GoodwillImpairmentLoss |
expense), and a charge of approximately $ 154.7 million to write down the disposal group to fair value, less cost to sell (recorded as a component of | text | 154.7 | monetaryItemType | text: <entity> 154.7 </entity> <entity type> monetaryItemType </entity type> <context> expense), and a charge of approximately $ 154.7 million to write down the disposal group to fair value, less cost to sell (recorded as a component of </context> | us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown |
in the consolidated statement of operations. During the year ended December 31, 2024, the Company recorded additional pre-tax charges of approximately $ 369.0 million to further write down the disposal group to fair value, less cost to sell. The additional charges were recorded as a component of | text | 369.0 | monetaryItemType | text: <entity> 369.0 </entity> <entity type> monetaryItemType </entity type> <context> in the consolidated statement of operations. During the year ended December 31, 2024, the Company recorded additional pre-tax charges of approximately $ 369.0 million to further write down the disposal group to fair value, less cost to sell. The additional charges were recorded as a component of </context> | us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown |
On October 1, 2023, Viatris executed an agreement to divest its API business in India to Matrix Pharma Private Limited, a privately held pharmaceutical company based in India. The transaction included three manufacturing sites and a R&D lab in Hyderabad, three manufacturing sites in Vizag and third-party API sales. Viatris retained some selective R&D capabilities in API. The transaction closed in June 2024. The API business in India met the criteria to be classified as held for sale on October 1, 2023 and the related assets and liabilities were reclassified as held for sale in the consolidated balance sheet as of December 31, 2023. During the year ended December 31, 2024, the Company recognized pre-tax charges of approximately $ 47.8 million on the disposal of the business, which were recorded as a component of | text | 47.8 | monetaryItemType | text: <entity> 47.8 </entity> <entity type> monetaryItemType </entity type> <context> On October 1, 2023, Viatris executed an agreement to divest its API business in India to Matrix Pharma Private Limited, a privately held pharmaceutical company based in India. The transaction included three manufacturing sites and a R&D lab in Hyderabad, three manufacturing sites in Vizag and third-party API sales. Viatris retained some selective R&D capabilities in API. The transaction closed in June 2024. The API business in India met the criteria to be classified as held for sale on October 1, 2023 and the related assets and liabilities were reclassified as held for sale in the consolidated balance sheet as of December 31, 2023. During the year ended December 31, 2024, the Company recognized pre-tax charges of approximately $ 47.8 million on the disposal of the business, which were recorded as a component of </context> | us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of | text | 374.2 | monetaryItemType | text: <entity> 374.2 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of </context> | us-gaap:AssetImpairmentCharges |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of | text | 117.0 | monetaryItemType | text: <entity> 117.0 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of </context> | us-gaap:GoodwillImpairmentLoss |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of | text | 84.3 | monetaryItemType | text: <entity> 84.3 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of </context> | us-gaap:AssetImpairmentCharges |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of | text | 172.9 | monetaryItemType | text: <entity> 172.9 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of </context> | us-gaap:ImpairmentOfIntangibleAssetsFinitelived |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of | text | 136.4 | monetaryItemType | text: <entity> 136.4 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of </context> | us-gaap:AssetImpairmentCharges |
In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of | text | 85.2 | monetaryItemType | text: <entity> 85.2 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2022, the commercialization rights in the Upjohn Distributor Markets met the criteria to be classified as held for sale. Upon classification as held for sale, the Company recognized a total charge of $ 374.2 million in 2022, which was comprised of a goodwill impairment charge of $ 117.0 million, other charges, principally inventory write-offs, of $ 84.3 million and a charge of approximately $ 172.9 million to write down the disposal group to fair value, less cost to sell. During the year ended December 31, 2023, the Company recorded charges totaling $ 136.4 million, primarily consisting of losses on the disposals of $ 85.2 million, which were recorded as a component of </context> | us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal |
On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billion of CCPS representing a stake of approximately 12.9 % (on a fully diluted basis) in Biocon Biologics at closing. During the years ended December 31, 2024 and 2023, the Company recorded a gain of $ 373.5 million and a loss of $ 21.1 million, respectively, as a result of remeasuring the CCPS in Biocon Biologics to fair value. The current year gain is primarily related to changes in certain market factors, including Biocon’s share price. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billion of CCPS representing a stake of approximately 12.9 % (on a fully diluted basis) in Biocon Biologics at closing. During the years ended December 31, 2024 and 2023, the Company recorded a gain of $ 373.5 million and a loss of $ 21.1 million, respectively, as a result of remeasuring the CCPS in Biocon Biologics to fair value. The current year gain is primarily related to changes in certain market factors, including Biocon’s share price. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in </context> | us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration |
On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billion of CCPS representing a stake of approximately 12.9 % (on a fully diluted basis) in Biocon Biologics at closing. During the years ended December 31, 2024 and 2023, the Company recorded a gain of $ 373.5 million and a loss of $ 21.1 million, respectively, as a result of remeasuring the CCPS in Biocon Biologics to fair value. The current year gain is primarily related to changes in certain market factors, including Biocon’s share price. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billion of CCPS representing a stake of approximately 12.9 % (on a fully diluted basis) in Biocon Biologics at closing. During the years ended December 31, 2024 and 2023, the Company recorded a gain of $ 373.5 million and a loss of $ 21.1 million, respectively, as a result of remeasuring the CCPS in Biocon Biologics to fair value. The current year gain is primarily related to changes in certain market factors, including Biocon’s share price. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in </context> | us-gaap:ProceedsFromDivestitureOfBusinesses |
On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billion of CCPS representing a stake of approximately 12.9 % (on a fully diluted basis) in Biocon Biologics at closing. During the years ended December 31, 2024 and 2023, the Company recorded a gain of $ 373.5 million and a loss of $ 21.1 million, respectively, as a result of remeasuring the CCPS in Biocon Biologics to fair value. The current year gain is primarily related to changes in certain market factors, including Biocon’s share price. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billion of CCPS representing a stake of approximately 12.9 % (on a fully diluted basis) in Biocon Biologics at closing. During the years ended December 31, 2024 and 2023, the Company recorded a gain of $ 373.5 million and a loss of $ 21.1 million, respectively, as a result of remeasuring the CCPS in Biocon Biologics to fair value. The current year gain is primarily related to changes in certain market factors, including Biocon’s share price. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in </context> | us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1 |
On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billion of CCPS representing a stake of approximately 12.9 % (on a fully diluted basis) in Biocon Biologics at closing. During the years ended December 31, 2024 and 2023, the Company recorded a gain of $ 373.5 million and a loss of $ 21.1 million, respectively, as a result of remeasuring the CCPS in Biocon Biologics to fair value. The current year gain is primarily related to changes in certain market factors, including Biocon’s share price. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in | text | 373.5 | monetaryItemType | text: <entity> 373.5 </entity> <entity type> monetaryItemType </entity type> <context> On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billion of CCPS representing a stake of approximately 12.9 % (on a fully diluted basis) in Biocon Biologics at closing. During the years ended December 31, 2024 and 2023, the Company recorded a gain of $ 373.5 million and a loss of $ 21.1 million, respectively, as a result of remeasuring the CCPS in Biocon Biologics to fair value. The current year gain is primarily related to changes in certain market factors, including Biocon’s share price. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in </context> | us-gaap:EquitySecuritiesFvNiGainLoss |
On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billion of CCPS representing a stake of approximately 12.9 % (on a fully diluted basis) in Biocon Biologics at closing. During the years ended December 31, 2024 and 2023, the Company recorded a gain of $ 373.5 million and a loss of $ 21.1 million, respectively, as a result of remeasuring the CCPS in Biocon Biologics to fair value. The current year gain is primarily related to changes in certain market factors, including Biocon’s share price. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in | text | 21.1 | monetaryItemType | text: <entity> 21.1 </entity> <entity type> monetaryItemType </entity type> <context> On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics. Under the terms of the Biocon Agreement, Viatris received $ 3 billion in consideration in the form of a $ 2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $ 1 billion of CCPS representing a stake of approximately 12.9 % (on a fully diluted basis) in Biocon Biologics at closing. During the years ended December 31, 2024 and 2023, the Company recorded a gain of $ 373.5 million and a loss of $ 21.1 million, respectively, as a result of remeasuring the CCPS in Biocon Biologics to fair value. The current year gain is primarily related to changes in certain market factors, including Biocon’s share price. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in </context> | us-gaap:EquitySecuritiesFvNiGainLoss |
The Biocon Agreement provided for a closing working capital target of $ 250 million, of which $ 220 million was paid by Viatris to Biocon Biologics during 2023. In addition, pursuant to the terms of the Biocon Agreement, the Company was entitled to receive a total of $ 335 million of additional cash payments in 2024 as deferred consideration. The Company received $ 245 million in deferred cash consideration payments from Biocon Biologics during 2024, and Viatris and Biocon Biologics agreed to offset certain amounts due between the parties, including the remaining $ 30 million of the closing working capital target, against the deferred cash consideration. In conjunction with the final settlement of amounts due between the parties, the Company recorded a pre-tax loss of $ 60.0 million as a component of | text | 60.0 | monetaryItemType | text: <entity> 60.0 </entity> <entity type> monetaryItemType </entity type> <context> The Biocon Agreement provided for a closing working capital target of $ 250 million, of which $ 220 million was paid by Viatris to Biocon Biologics during 2023. In addition, pursuant to the terms of the Biocon Agreement, the Company was entitled to receive a total of $ 335 million of additional cash payments in 2024 as deferred consideration. The Company received $ 245 million in deferred cash consideration payments from Biocon Biologics during 2024, and Viatris and Biocon Biologics agreed to offset certain amounts due between the parties, including the remaining $ 30 million of the closing working capital target, against the deferred cash consideration. In conjunction with the final settlement of amounts due between the parties, the Company recorded a pre-tax loss of $ 60.0 million as a component of </context> | us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal |
Upon closing of the Biocon Biologics Transaction, the Company recognized a gain on sale of approximately $ 1.75 billion for the difference between the consideration received, including the fair value of the CCPS, and the carrying value of the biosimilars portfolio (including an allocation of goodwill). The gain was recognized as a component of | text | 1.75 | monetaryItemType | text: <entity> 1.75 </entity> <entity type> monetaryItemType </entity type> <context> Upon closing of the Biocon Biologics Transaction, the Company recognized a gain on sale of approximately $ 1.75 billion for the difference between the consideration received, including the fair value of the CCPS, and the carrying value of the biosimilars portfolio (including an allocation of goodwill). The gain was recognized as a component of </context> | us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal |
Inventory reserves totaled $ 454.5 million and $ 479.3 million at December 31, 2024 and 2023, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $ 289.3 million, $ 226.9 million and $ 326.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 454.5 | monetaryItemType | text: <entity> 454.5 </entity> <entity type> monetaryItemType </entity type> <context> Inventory reserves totaled $ 454.5 million and $ 479.3 million at December 31, 2024 and 2023, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $ 289.3 million, $ 226.9 million and $ 326.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:InventoryValuationReserves |
Inventory reserves totaled $ 454.5 million and $ 479.3 million at December 31, 2024 and 2023, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $ 289.3 million, $ 226.9 million and $ 326.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 479.3 | monetaryItemType | text: <entity> 479.3 </entity> <entity type> monetaryItemType </entity type> <context> Inventory reserves totaled $ 454.5 million and $ 479.3 million at December 31, 2024 and 2023, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $ 289.3 million, $ 226.9 million and $ 326.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:InventoryValuationReserves |
Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $ 357.0 million, $ 362.1 million and $ 349.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 157.7 | monetaryItemType | text: <entity> 157.7 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $ 357.0 million, $ 362.1 million and $ 349.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:CapitalizedComputerSoftwareNet |
Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $ 357.0 million, $ 362.1 million and $ 349.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 167.2 | monetaryItemType | text: <entity> 167.2 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $ 357.0 million, $ 362.1 million and $ 349.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:CapitalizedComputerSoftwareNet |
Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $ 357.0 million, $ 362.1 million and $ 349.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 357.0 | monetaryItemType | text: <entity> 357.0 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $ 357.0 million, $ 362.1 million and $ 349.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:Depreciation |
Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $ 357.0 million, $ 362.1 million and $ 349.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 362.1 | monetaryItemType | text: <entity> 362.1 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $ 357.0 million, $ 362.1 million and $ 349.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:Depreciation |
Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $ 357.0 million, $ 362.1 million and $ 349.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 349.5 | monetaryItemType | text: <entity> 349.5 </entity> <entity type> monetaryItemType </entity type> <context> Capitalized software costs included in our consolidated balance sheets were $ 157.7 million and $ 167.2 million, net of accumulated depreciation, at December 31, 2024 and 2023, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $ 357.0 million, $ 362.1 million and $ 349.5 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:Depreciation |
The Company has certain voluntary supply chain finance programs with financial intermediaries which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. The range of payment terms the Company negotiates with suppliers are consistent, regardless of whether a supplier participates in a supply chain finance program. The total amounts due to financial intermediaries to settle supplier invoices under supply chain finance programs as of December 31, 2024 and 2023 were $ 41.9 million and $ 65.1 million, respectively. These amounts are included within | text | 41.9 | monetaryItemType | text: <entity> 41.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company has certain voluntary supply chain finance programs with financial intermediaries which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. The range of payment terms the Company negotiates with suppliers are consistent, regardless of whether a supplier participates in a supply chain finance program. The total amounts due to financial intermediaries to settle supplier invoices under supply chain finance programs as of December 31, 2024 and 2023 were $ 41.9 million and $ 65.1 million, respectively. These amounts are included within </context> | us-gaap:SupplierFinanceProgramObligation |
The Company has certain voluntary supply chain finance programs with financial intermediaries which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. The range of payment terms the Company negotiates with suppliers are consistent, regardless of whether a supplier participates in a supply chain finance program. The total amounts due to financial intermediaries to settle supplier invoices under supply chain finance programs as of December 31, 2024 and 2023 were $ 41.9 million and $ 65.1 million, respectively. These amounts are included within | text | 65.1 | monetaryItemType | text: <entity> 65.1 </entity> <entity type> monetaryItemType </entity type> <context> The Company has certain voluntary supply chain finance programs with financial intermediaries which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. The range of payment terms the Company negotiates with suppliers are consistent, regardless of whether a supplier participates in a supply chain finance program. The total amounts due to financial intermediaries to settle supplier invoices under supply chain finance programs as of December 31, 2024 and 2023 were $ 41.9 million and $ 65.1 million, respectively. These amounts are included within </context> | us-gaap:SupplierFinanceProgramObligation |
Balance as of December 31, 2024 includes a total of $ 378.0 million related to the Idorsia Transaction. Refer to Note 9 | text | 378.0 | monetaryItemType | text: <entity> 378.0 </entity> <entity type> monetaryItemType </entity type> <context> Balance as of December 31, 2024 includes a total of $ 378.0 million related to the Idorsia Transaction. Refer to Note 9 </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
As of December 31, 2024, the Company recognized ROU assets of $ 253.1 million and total lease liabilities of $ 266.4 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance sheets. Refer to Note 6 | text | 253.1 | monetaryItemType | text: <entity> 253.1 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company recognized ROU assets of $ 253.1 million and total lease liabilities of $ 266.4 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance sheets. Refer to Note 6 </context> | us-gaap:OperatingLeaseRightOfUseAsset |
As of December 31, 2024, the Company recognized ROU assets of $ 253.1 million and total lease liabilities of $ 266.4 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance sheets. Refer to Note 6 | text | 266.4 | monetaryItemType | text: <entity> 266.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company recognized ROU assets of $ 253.1 million and total lease liabilities of $ 266.4 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance sheets. Refer to Note 6 </context> | us-gaap:OperatingLeaseLiability |
As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had operating lease expense of approximately $ 89.8 million, $ 87.6 million and $ 90.9 million, respectively. Operating lease costs are classified primarily as SG&A and cost of sales in the consolidated statements of operations. | text | 89.8 | monetaryItemType | text: <entity> 89.8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had operating lease expense of approximately $ 89.8 million, $ 87.6 million and $ 90.9 million, respectively. Operating lease costs are classified primarily as SG&A and cost of sales in the consolidated statements of operations. </context> | us-gaap:PaymentsForRent |
As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had operating lease expense of approximately $ 89.8 million, $ 87.6 million and $ 90.9 million, respectively. Operating lease costs are classified primarily as SG&A and cost of sales in the consolidated statements of operations. | text | 87.6 | monetaryItemType | text: <entity> 87.6 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had operating lease expense of approximately $ 89.8 million, $ 87.6 million and $ 90.9 million, respectively. Operating lease costs are classified primarily as SG&A and cost of sales in the consolidated statements of operations. </context> | us-gaap:PaymentsForRent |
As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had operating lease expense of approximately $ 89.8 million, $ 87.6 million and $ 90.9 million, respectively. Operating lease costs are classified primarily as SG&A and cost of sales in the consolidated statements of operations. | text | 90.9 | monetaryItemType | text: <entity> 90.9 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had additional leases, primarily for administrative offices, that have not yet commenced totaling approximately $ 5.8 million. For the years ended December 31, 2024, 2023 and 2022, the Company had operating lease expense of approximately $ 89.8 million, $ 87.6 million and $ 90.9 million, respectively. Operating lease costs are classified primarily as SG&A and cost of sales in the consolidated statements of operations. </context> | us-gaap:PaymentsForRent |
Balances as of December 31, 2024 and 2023 include an accumulated impairment loss of $ 929.0 million. Balance as of December 31, 2022 includes an accumulated impairment loss of $ 385.0 million. | text | 385.0 | monetaryItemType | text: <entity> 385.0 </entity> <entity type> monetaryItemType </entity type> <context> Balances as of December 31, 2024 and 2023 include an accumulated impairment loss of $ 929.0 million. Balance as of December 31, 2022 includes an accumulated impairment loss of $ 385.0 million. </context> | us-gaap:GoodwillImpairedAccumulatedImpairmentLoss |
Balance as of December 31, 2024 includes an accumulated impairment loss of $ 351.0 million. Balance as of December 31, 2023 includes an accumulated impairment loss of $ 30.0 million. | text | 351.0 | monetaryItemType | text: <entity> 351.0 </entity> <entity type> monetaryItemType </entity type> <context> Balance as of December 31, 2024 includes an accumulated impairment loss of $ 351.0 million. Balance as of December 31, 2023 includes an accumulated impairment loss of $ 30.0 million. </context> | us-gaap:GoodwillImpairedAccumulatedImpairmentLoss |
Balance as of December 31, 2024 includes an accumulated impairment loss of $ 351.0 million. Balance as of December 31, 2023 includes an accumulated impairment loss of $ 30.0 million. | text | 30.0 | monetaryItemType | text: <entity> 30.0 </entity> <entity type> monetaryItemType </entity type> <context> Balance as of December 31, 2024 includes an accumulated impairment loss of $ 351.0 million. Balance as of December 31, 2023 includes an accumulated impairment loss of $ 30.0 million. </context> | us-gaap:GoodwillImpairedAccumulatedImpairmentLoss |
Balances as of December 31, 2024 and 2023 include an accumulated impairment loss of $ 124.0 million. Balance as of December 31, 2022 includes an accumulated impairment loss of $ 117.0 million. | text | 117.0 | monetaryItemType | text: <entity> 117.0 </entity> <entity type> monetaryItemType </entity type> <context> Balances as of December 31, 2024 and 2023 include an accumulated impairment loss of $ 124.0 million. Balance as of December 31, 2022 includes an accumulated impairment loss of $ 117.0 million. </context> | us-gaap:GoodwillImpairedAccumulatedImpairmentLoss |
In conjunction with its annual goodwill impairment test, the Company recorded a goodwill impairment charge of $ 321.0 million during the second quarter of 2024 related to its JANZ reporting unit, which was recorded within | text | 321.0 | monetaryItemType | text: <entity> 321.0 </entity> <entity type> monetaryItemType </entity type> <context> In conjunction with its annual goodwill impairment test, the Company recorded a goodwill impairment charge of $ 321.0 million during the second quarter of 2024 related to its JANZ reporting unit, which was recorded within </context> | us-gaap:GoodwillImpairmentLoss |
For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $ 882 million or 7.9 % for the annual goodwill impairment test. As it relates to the discounted cash flow approach for the Europe reporting unit at April 1, 2024, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately 2.5 %. A terminal year value was calculated with a 2.0 % revenue growth rate applied. The discount rate utilized was 10.0 % and the estimated tax rate was 15.7 %. If all other assumptions are held constant, a reduction in the terminal value growth rate by 1.5 % or an increase in discount rate by 1.0 % would result in an impairment charge for the Europe reporting unit. | text | 882 | monetaryItemType | text: <entity> 882 </entity> <entity type> monetaryItemType </entity type> <context> For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $ 882 million or 7.9 % for the annual goodwill impairment test. As it relates to the discounted cash flow approach for the Europe reporting unit at April 1, 2024, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately 2.5 %. A terminal year value was calculated with a 2.0 % revenue growth rate applied. The discount rate utilized was 10.0 % and the estimated tax rate was 15.7 %. If all other assumptions are held constant, a reduction in the terminal value growth rate by 1.5 % or an increase in discount rate by 1.0 % would result in an impairment charge for the Europe reporting unit. </context> | us-gaap:ReportingUnitAmountOfFairValueInExcessOfCarryingAmount |
For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $ 882 million or 7.9 % for the annual goodwill impairment test. As it relates to the discounted cash flow approach for the Europe reporting unit at April 1, 2024, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately 2.5 %. A terminal year value was calculated with a 2.0 % revenue growth rate applied. The discount rate utilized was 10.0 % and the estimated tax rate was 15.7 %. If all other assumptions are held constant, a reduction in the terminal value growth rate by 1.5 % or an increase in discount rate by 1.0 % would result in an impairment charge for the Europe reporting unit. | text | 7.9 | percentItemType | text: <entity> 7.9 </entity> <entity type> percentItemType </entity type> <context> For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $ 882 million or 7.9 % for the annual goodwill impairment test. As it relates to the discounted cash flow approach for the Europe reporting unit at April 1, 2024, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately 2.5 %. A terminal year value was calculated with a 2.0 % revenue growth rate applied. The discount rate utilized was 10.0 % and the estimated tax rate was 15.7 %. If all other assumptions are held constant, a reduction in the terminal value growth rate by 1.5 % or an increase in discount rate by 1.0 % would result in an impairment charge for the Europe reporting unit. </context> | us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount |
In the third quarter of 2023, the Company allocated goodwill of $ 69 million to its women’s healthcare business using a relative fair value approach and reclassified the amount to | text | 69 | monetaryItemType | text: <entity> 69 </entity> <entity type> monetaryItemType </entity type> <context> In the third quarter of 2023, the Company allocated goodwill of $ 69 million to its women’s healthcare business using a relative fair value approach and reclassified the amount to </context> | us-gaap:GoodwillTransfers |
In the fourth quarter of 2023, the Company allocated goodwill of $ 120 million to its API business in India using a relative fair value approach and reclassified the amount to | text | 120 | monetaryItemType | text: <entity> 120 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2023, the Company allocated goodwill of $ 120 million to its API business in India using a relative fair value approach and reclassified the amount to </context> | us-gaap:GoodwillTransfers |
In the fourth quarter of 2023, the OTC Business met the criteria to be classified as held for sale. The Company allocated goodwill to its OTC Business using a relative fair value approach and recorded a goodwill impairment charge of $ 580.1 million in that quarter within the Europe (majority of the charge), JANZ and Emerging Markets reporting units, which was recorded within | text | 580.1 | monetaryItemType | text: <entity> 580.1 </entity> <entity type> monetaryItemType </entity type> <context> In the fourth quarter of 2023, the OTC Business met the criteria to be classified as held for sale. The Company allocated goodwill to its OTC Business using a relative fair value approach and recorded a goodwill impairment charge of $ 580.1 million in that quarter within the Europe (majority of the charge), JANZ and Emerging Markets reporting units, which was recorded within </context> | us-gaap:GoodwillImpairmentLoss |
During the years ended December 31, 2023 and 2022, the Company recognized intangible asset charges of approximately $ 32.0 million and $ 172.9 million, respectively, recorded within | text | 32.0 | monetaryItemType | text: <entity> 32.0 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2023 and 2022, the Company recognized intangible asset charges of approximately $ 32.0 million and $ 172.9 million, respectively, recorded within </context> | us-gaap:ImpairmentOfIntangibleAssetsFinitelived |
During the years ended December 31, 2023 and 2022, the Company recognized intangible asset charges of approximately $ 32.0 million and $ 172.9 million, respectively, recorded within | text | 172.9 | monetaryItemType | text: <entity> 172.9 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2023 and 2022, the Company recognized intangible asset charges of approximately $ 32.0 million and $ 172.9 million, respectively, recorded within </context> | us-gaap:ImpairmentOfIntangibleAssetsFinitelived |
The Company de-designated € 189.2 million of the 2.250 % Euro Senior Notes due 2024 as net investment hedges in the third quarter of 2024 and an additional € 200.0 million in October 2024. The Euro Senior Notes were repaid at maturity during the fourth quarter of 2024. | text | 2.250 | percentItemType | text: <entity> 2.250 </entity> <entity type> percentItemType </entity type> <context> The Company de-designated € 189.2 million of the 2.250 % Euro Senior Notes due 2024 as net investment hedges in the third quarter of 2024 and an additional € 200.0 million in October 2024. The Euro Senior Notes were repaid at maturity during the fourth quarter of 2024. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
for more information), the Company de-designated the € 500 million 2.125 % Euro Senior Notes due 2025 as net investment hedges. The remaining Senior Notes were fully redeemed in October 2024. | text | 2.125 | percentItemType | text: <entity> 2.125 </entity> <entity type> percentItemType </entity type> <context> for more information), the Company de-designated the € 500 million 2.125 % Euro Senior Notes due 2025 as net investment hedges. The remaining Senior Notes were fully redeemed in October 2024. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
The principal amount of the foreign currency forward contracts at December 31, 2023 was € 500 million. The contracts matured in July 2024. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> The principal amount of the foreign currency forward contracts at December 31, 2023 was € 500 million. The contracts matured in July 2024. </context> | us-gaap:DerivativeAssetNotionalAmount |
At December 31, 2024, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedges was $ 254.4 million. | text | 254.4 | monetaryItemType | text: <entity> 254.4 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedges was $ 254.4 million. </context> | us-gaap:LongTermDebt |
During the third quarter of 2023, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling Japanese Yen 14.6 billion with settlement dates through 2026. During the second quarter of 2024, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling € 500 million with settlement dates through 2026. The transactions hedge a portion of the Company’s net investment in certain Yen- and Euro-functional currency subsidiaries. All changes in the fair value of these derivative instruments, which are designated as net investment hedges, are marked-to-market using the current spot exchange rate as of the end of the period. The portion of these changes related to the excluded component will be amortized in interest expense over the life of the derivative while the remainder will be recorded in AOCE until the sale or substantial liquidation of the underlying net investments. The semiannual net interest payment received related to the fixed-rate component of the cross-currency interest rate swaps will be reflected in operating cash flows. | text | 14.6 | monetaryItemType | text: <entity> 14.6 </entity> <entity type> monetaryItemType </entity type> <context> During the third quarter of 2023, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling Japanese Yen 14.6 billion with settlement dates through 2026. During the second quarter of 2024, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling € 500 million with settlement dates through 2026. The transactions hedge a portion of the Company’s net investment in certain Yen- and Euro-functional currency subsidiaries. All changes in the fair value of these derivative instruments, which are designated as net investment hedges, are marked-to-market using the current spot exchange rate as of the end of the period. The portion of these changes related to the excluded component will be amortized in interest expense over the life of the derivative while the remainder will be recorded in AOCE until the sale or substantial liquidation of the underlying net investments. The semiannual net interest payment received related to the fixed-rate component of the cross-currency interest rate swaps will be reflected in operating cash flows. </context> | us-gaap:DerivativeNotionalAmount |
During the third quarter of 2023, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling Japanese Yen 14.6 billion with settlement dates through 2026. During the second quarter of 2024, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling € 500 million with settlement dates through 2026. The transactions hedge a portion of the Company’s net investment in certain Yen- and Euro-functional currency subsidiaries. All changes in the fair value of these derivative instruments, which are designated as net investment hedges, are marked-to-market using the current spot exchange rate as of the end of the period. The portion of these changes related to the excluded component will be amortized in interest expense over the life of the derivative while the remainder will be recorded in AOCE until the sale or substantial liquidation of the underlying net investments. The semiannual net interest payment received related to the fixed-rate component of the cross-currency interest rate swaps will be reflected in operating cash flows. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> During the third quarter of 2023, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling Japanese Yen 14.6 billion with settlement dates through 2026. During the second quarter of 2024, the Company executed fixed-rate cross-currency interest rate swaps with notional amounts totaling € 500 million with settlement dates through 2026. The transactions hedge a portion of the Company’s net investment in certain Yen- and Euro-functional currency subsidiaries. All changes in the fair value of these derivative instruments, which are designated as net investment hedges, are marked-to-market using the current spot exchange rate as of the end of the period. The portion of these changes related to the excluded component will be amortized in interest expense over the life of the derivative while the remainder will be recorded in AOCE until the sale or substantial liquidation of the underlying net investments. The semiannual net interest payment received related to the fixed-rate component of the cross-currency interest rate swaps will be reflected in operating cash flows. </context> | us-gaap:DerivativeNotionalAmount |
During the fourth quarter of 2023, the Company executed foreign currency forward contracts with notional amounts totaling € 500 million. During the second quarter of 2024, the Company executed additional foreign currency forward contracts with notional amounts totaling € 600 million. The transactions hedged a portion of the Company’s net investment in certain Euro functional currency subsidiaries. The contracts were designated as a net investment hedge and matured in July 2024. | text | 500 | monetaryItemType | text: <entity> 500 </entity> <entity type> monetaryItemType </entity type> <context> During the fourth quarter of 2023, the Company executed foreign currency forward contracts with notional amounts totaling € 500 million. During the second quarter of 2024, the Company executed additional foreign currency forward contracts with notional amounts totaling € 600 million. The transactions hedged a portion of the Company’s net investment in certain Euro functional currency subsidiaries. The contracts were designated as a net investment hedge and matured in July 2024. </context> | us-gaap:DerivativeNotionalAmount |
During the fourth quarter of 2023, the Company executed foreign currency forward contracts with notional amounts totaling € 500 million. During the second quarter of 2024, the Company executed additional foreign currency forward contracts with notional amounts totaling € 600 million. The transactions hedged a portion of the Company’s net investment in certain Euro functional currency subsidiaries. The contracts were designated as a net investment hedge and matured in July 2024. | text | 600 | monetaryItemType | text: <entity> 600 </entity> <entity type> monetaryItemType </entity type> <context> During the fourth quarter of 2023, the Company executed foreign currency forward contracts with notional amounts totaling € 500 million. During the second quarter of 2024, the Company executed additional foreign currency forward contracts with notional amounts totaling € 600 million. The transactions hedged a portion of the Company’s net investment in certain Euro functional currency subsidiaries. The contracts were designated as a net investment hedge and matured in July 2024. </context> | us-gaap:DerivativeNotionalAmount |
At December 31, 2024, the Company expects that approximately $ 19.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months. | text | 19.0 | monetaryItemType | text: <entity> 19.0 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, the Company expects that approximately $ 19.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months. </context> | us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths |
As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, and as of December 31, 2023, the Company had a contingent consideration liability of $ 15.8 million related to the Biocon Biologics Transaction. Refer to Note 5 | text | 378.0 | monetaryItemType | text: <entity> 378.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, and as of December 31, 2023, the Company had a contingent consideration liability of $ 15.8 million related to the Biocon Biologics Transaction. Refer to Note 5 </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, and as of December 31, 2023, the Company had a contingent consideration liability of $ 15.8 million related to the Biocon Biologics Transaction. Refer to Note 5 | text | 176.3 | monetaryItemType | text: <entity> 176.3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, and as of December 31, 2023, the Company had a contingent consideration liability of $ 15.8 million related to the Biocon Biologics Transaction. Refer to Note 5 </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, and as of December 31, 2023, the Company had a contingent consideration liability of $ 15.8 million related to the Biocon Biologics Transaction. Refer to Note 5 | text | 177.6 | monetaryItemType | text: <entity> 177.6 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, and as of December 31, 2023, the Company had a contingent consideration liability of $ 15.8 million related to the Biocon Biologics Transaction. Refer to Note 5 </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, and as of December 31, 2023, the Company had a contingent consideration liability of $ 15.8 million related to the Biocon Biologics Transaction. Refer to Note 5 | text | 15.8 | monetaryItemType | text: <entity> 15.8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had a contingent consideration liability of $ 378.0 million related to the Idorsia Transaction. As of December 31, 2024 and 2023, the Company had a contingent consideration liability of $ 176.3 million and $ 177.6 million, respectively, related to the Respiratory Delivery Platform, and as of December 31, 2023, the Company had a contingent consideration liability of $ 15.8 million related to the Biocon Biologics Transaction. Refer to Note 5 </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In addition, the agreement governing the Receivables Facility contains various customary affirmative and negative covenants, and customary default and termination provisions with which the Company was compliant as of December 31, 2024. As of December 31, 2024 and 2023, the Company had $ 484.1 million and $ 564.5 million, respectively, of accounts receivable balances sold to its subsidiary Mylan Securitization LLC under the Receivables Facility. | text | 0.775 | percentItemType | text: <entity> 0.775 </entity> <entity type> percentItemType </entity type> <context> Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In addition, the agreement governing the Receivables Facility contains various customary affirmative and negative covenants, and customary default and termination provisions with which the Company was compliant as of December 31, 2024. As of December 31, 2024 and 2023, the Company had $ 484.1 million and $ 564.5 million, respectively, of accounts receivable balances sold to its subsidiary Mylan Securitization LLC under the Receivables Facility. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In addition, the agreement governing the Receivables Facility contains various customary affirmative and negative covenants, and customary default and termination provisions with which the Company was compliant as of December 31, 2024. As of December 31, 2024 and 2023, the Company had $ 484.1 million and $ 564.5 million, respectively, of accounts receivable balances sold to its subsidiary Mylan Securitization LLC under the Receivables Facility. | text | 484.1 | monetaryItemType | text: <entity> 484.1 </entity> <entity type> monetaryItemType </entity type> <context> Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In addition, the agreement governing the Receivables Facility contains various customary affirmative and negative covenants, and customary default and termination provisions with which the Company was compliant as of December 31, 2024. As of December 31, 2024 and 2023, the Company had $ 484.1 million and $ 564.5 million, respectively, of accounts receivable balances sold to its subsidiary Mylan Securitization LLC under the Receivables Facility. </context> | us-gaap:AccountsReceivableFromSecuritization |
Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In addition, the agreement governing the Receivables Facility contains various customary affirmative and negative covenants, and customary default and termination provisions with which the Company was compliant as of December 31, 2024. As of December 31, 2024 and 2023, the Company had $ 484.1 million and $ 564.5 million, respectively, of accounts receivable balances sold to its subsidiary Mylan Securitization LLC under the Receivables Facility. | text | 564.5 | monetaryItemType | text: <entity> 564.5 </entity> <entity type> monetaryItemType </entity type> <context> Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775 % and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In addition, the agreement governing the Receivables Facility contains various customary affirmative and negative covenants, and customary default and termination provisions with which the Company was compliant as of December 31, 2024. As of December 31, 2024 and 2023, the Company had $ 484.1 million and $ 564.5 million, respectively, of accounts receivable balances sold to its subsidiary Mylan Securitization LLC under the Receivables Facility. </context> | us-gaap:AccountsReceivableFromSecuritization |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. | text | 1.650 | percentItemType | text: <entity> 1.650 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. | text | 2.125 | percentItemType | text: <entity> 2.125 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. | text | 422.3 | monetaryItemType | text: <entity> 422.3 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. </context> | us-gaap:EarlyRepaymentOfSeniorDebt |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. | text | 432.0 | monetaryItemType | text: <entity> 432.0 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. </context> | us-gaap:LongTermDebt |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. | text | 97.8 | percentItemType | text: <entity> 97.8 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. </context> | us-gaap:DebtInstrumentRedemptionPricePercentage |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. | text | 206.9 | monetaryItemType | text: <entity> 206.9 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. </context> | us-gaap:EarlyRepaymentOfSeniorDebt |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. | text | 208.1 | monetaryItemType | text: <entity> 208.1 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. </context> | us-gaap:LongTermDebt |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. | text | 99.4 | percentItemType | text: <entity> 99.4 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. </context> | us-gaap:DebtInstrumentRedemptionPricePercentage |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. | text | 3.950 | percentItemType | text: <entity> 3.950 </entity> <entity type> percentItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. </context> | us-gaap:DebtInstrumentInterestRateStatedPercentage |
On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. | text | 572.5 | monetaryItemType | text: <entity> 572.5 </entity> <entity type> monetaryItemType </entity type> <context> On September 16, 2024, Viatris and Mylan Inc. completed cash tender offers for their then-outstanding 1.650 % Senior Notes due 2025 (the “2025 Senior Notes”) and 2.125 % Senior Notes due 2025 (the “2025 Euro Senior Notes”), respectively. Viatris paid $ 422.3 million to repurchase $ 432.0 million aggregate principal amount of the 2025 Senior Notes at a repurchase price equal to 97.8 % of the aggregate principal amount of the 2025 Senior Notes accepted for tender, and also paid accrued and unpaid interest. Mylan Inc. paid € 206.9 million to repurchase € 208.1 million aggregate principal amount of the 2025 Euro Senior Notes at a repurchase price equal to 99.4 % of the aggregate principal amount of the 2025 Euro Senior Notes accepted for tender, and also paid accrued and unpaid interest. On September 20, 2024, Utah Acquisition Sub Inc. also completed a cash tender offer for its then-outstanding 3.950 % Senior Notes due 2026 (the “2026 Senior Notes” and, together with the 2025 Senior Notes and the 2025 Euro Senior Notes, the “Senior Notes”) and paid $ 572.5 million to repurchase $ 575.0 million aggregate principal amount at a repurchase price equal to 99.6 % of the aggregate principal amount of the 2026 Senior Notes accepted for tender, and also paid accrued and unpaid interest. </context> | us-gaap:EarlyRepaymentOfSeniorDebt |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.